Live Event – All Hands On Deck In The Treatment Of Major Depressive Disorder (MDD): A Focus On Measurement-Based Care In Psychiatry & Primary Care
This is a Live Event for PsychU members in New York City, Westchster, and Long Island, NY.
Given the current state of affairs, primary care providers are increasingly treating patients with Major Depressive Disorder (MDD). During this panel presentation, our speakers will be discussing the prevalence and burden of MDD and the impact of COVID-19 on MDD. Additionally, they will discuss barriers faced by primary care providers and include the perspectives and expertise from psychiatrists. Finally, the presenters will consider the potential role of measurement-based care, focusing on the strategies incorporated in their practices and discussing methods of collaboration.
Objectives:
- Discuss the prevalence and burden of Major Depressive Disorder (MDD) locally and nationally, including the impact of COVID-19
- Identify gaps between primary care and psychiatry within treatment of MDD
- Understand the potential role and importance of measurement-based care (MBC)
- Consider methods of collaboration that may improve outcomes for patients with MDD
Joseph Goldberg, MD
Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai
More
Joseph F. Goldberg, MD is Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai. He attended college at the University of Chicago, graduate school in neuroscience at the University of Illinois, and medical school at Northwestern University. He completed his residency and chief residency in psychiatry, and fellowship in psychopharmacology, at the Payne Whitney Clinic, New York Presbyterian Hospital, where he later served on the faculty and was site Principal Investigator at Weill-Cornell Medical Center for the NIMH STEP-BD program. He has published over 200 peer-reviewed papers on topics related mainly to the treatment and clinical features of bipolar disorder, as well as three books on bipolar disorder and psychopharmacology, most recently “Managing the Side Effects of Psychotropic Medications, 2nd edition” published in 2019 by American Psychiatric Publishing, and the forthcoming “Practical Psychopharmacology” by Cambridge University Press. He serves on the Board of Directors for the American Society of Clinical Psychopharmacology and is on the editorial boards for a number of peer-reviewed journals. His research has been awarded funding from NARSAD, NIMH, the Stanley Foundation, and the American Foundation for Suicide Prevention. Dr. Goldberg is a Distinguished Fellow of the American Psychiatric Association and has been listed for many years in Best Doctors in America and Castle Connolly’s “America’s Top Doctors.”
Darcy Leon, PMHNP-BC
Psychiatric Nurse Practitioner
More
Darcy Leon is a psychiatric nurse practitioner currently working in outpatient psychiatry in Tarrytown, NY. She specializes in the treatment of mood disorders, traumatic brain injury, substance use disorders, and treatment-refractory psychiatric illnesses. Darcy also has a specific interest in psychodynamic psychopharmacology, which she employs to better connect patients with the ways their personal experiences interact with medication treatments.
C. Brendan Montano, MD, PC
Director and Principal Investigator for Connecticut Clinical Research in Cromwell, Connecticut
More
Brendan Montano, MD, is the owner and medical director of Montano Wellness, LLC, and director of and a principal investigator for CT Clinical Research, all in Cromwell, Connecticut. Dr Montano is also an attending physician at Middlesex Memorial Hospital in Middletown, Connecticut, a clinical instructor at Springfield College in Springfield, Massachusetts, and a primary care section advisor online for PsychU. He earned his medical degree from Albany College in Albany, New York. He completed his residency in internal medicine at Saint Francis Hospital and Medical Center in Hartford, Connecticut. Dr Montano has served as a principal investigator for over 120 clinical trials to evaluate the safety and efficacy of novel therapeutics for indications such as attention-deficit/hyperactivity disorder, major depressive disorder, and many other psychiatric and neurologic conditions. He is an editorial board member of The Primary Care Companion for CNS Disorders.
Michael Townsend, MA, LSW/LCSW
Deputy Chief Executive Officer, Gateway Counseling Center
More
Mr. Townsend, is the Deputy Chief Executive Officer at Gateway Counseling Center where he assists the Chief Executive Officer (CEO) with managing and directing the organization towards its primary objectives, serves as a member of the Boardof Directors, as well as the Chair of Audit Committee of the Mental Health Association in New York, and is also the President of GCC Transportation, LLC, which directs transportation services to the transit disabled and medically frail.
Jehan Marino, PharmD, BCPP
Medical Science Liaison
Erika Modh, PharmD, BCPS
Medical Science Liaison
Speakers Joseph Goldberg, MD; Darcy Leon, PMHNP-BC; C. Brendan Montano, MD, PC; and Michael Townsend, MA, LCSW are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc.
Speakers Jehan Marino, PharmD, BCPP and Erika Modh, PharmD, BCPS are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS
PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.
PSYCHU MEMBERSHIP ELIGIBILITY
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients.
NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.
MEMBERSHIP & REGISTRATION
Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.
ATTENDANCE LIMITATIONS
PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.
MEAL REPORTING
The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.
